Query author contributions in Reactome Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome .
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person FLT mutants bind type I TKIs
Class:Id Reaction:9702508 _displayName FLT mutants bind type I TKIs _doRelease TRUE _timestamp 2020-11-06 20:53:26 authored [InstanceEdit:9706566] Rothfels, Karen, 2020-11-06 compartment [Compartment:876] plasma membrane [Compartment:70101] cytosol created [InstanceEdit:9702511] Rothfels, Karen, 2020-09-30 disease [Disease:1500689] cancer edited [InstanceEdit:9706566] Rothfels, Karen, 2020-11-06 input [DefinedSet:9695790] type I FLT3-binding TKIs [cytosol] [DefinedSet:9702522] type I TKI sensitive FLT3 mutants [plasma membrane] [Homo sapiens] isChimeric FALSE literatureReference [LiteratureReference:9671447] Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases [LiteratureReference:9695653] FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions [LiteratureReference:9703031] The importance of FLT3 mutational analysis in acute myeloid leukemia [LiteratureReference:9683353] Targeting FLT3 mutations in AML: review of current knowledge and evidence [LiteratureReference:9699279] FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors [LiteratureReference:9699248] Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants [LiteratureReference:9691838] Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles [LiteratureReference:9699345] Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors [LiteratureReference:9699384] The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib [LiteratureReference:9699271] Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia [LiteratureReference:9702890] The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases [LiteratureReference:9699304] FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro [LiteratureReference:9699314] Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations [LiteratureReference:9699321] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia [LiteratureReference:9697855] Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival [LiteratureReference:9691830] SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase [LiteratureReference:9697850] Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells [LiteratureReference:9702472] KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation [LiteratureReference:9702959] FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia [LiteratureReference:9702964] TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo [LiteratureReference:9702972] The multitargeted receptor tyrosine kinase inhibitor linifanib (ABT-869) induces apoptosis through an Akt and glycogen synthase kinase 3β-dependent pathway modified [InstanceEdit:9702648] Rothfels, Karen, 2020-10-01 [InstanceEdit:9702943] Rothfels, Karen, 2020-10-02 [InstanceEdit:9703062] Rothfels, Karen, 2020-10-05 [InstanceEdit:9706570] Rothfels, Karen, 2020-11-06 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08 name FLT mutants bind type I TKIs normalReaction
output [Complex:9702642] type I TKI-sensitive FLT3 mutants:type I TKIs [plasma membrane] [Homo sapiens] releaseDate 2020-12-08 reviewed [InstanceEdit:9706568] Kazi, Julhash U, 2020-11-06 reviewStatus [ReviewStatus:9821382] five stars species [Species:48887] Homo sapiens stableIdentifier [StableIdentifier:9702512] R-HSA-9702508.2 summation [Summation:9702922] Type I tyrosine kinase inhibitors bind to the ATP-binding si... (hasEvent) [Pathway:9702509] FLT3 mutants bind TKIs [Homo sapiens]
[Change default viewing format]
List...
Protein identifiers
ChEBI identifiers
KEGG COMPOUND identifiers
No pathways have been reviewed or authored by FLT mutants bind type I TKIs (9702508)
